iRadimed (NASDAQ:IRMD) CEO Sells $370,171.12 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 4,411 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $83.92, for a total transaction of $370,171.12. Following the completion of the transaction, the chief executive officer directly owned 2,180,000 shares of the company’s stock, valued at approximately $182,945,600. This trade represents a 0.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Down 0.5%

NASDAQ IRMD opened at $86.44 on Friday. The company has a fifty day moving average of $93.68 and a two-hundred day moving average of $94.67. The firm has a market capitalization of $1.10 billion, a price-to-earnings ratio of 47.24 and a beta of 0.90. iRadimed Corporation has a 52 week low of $50.88 and a 52 week high of $107.90.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities research analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s payout ratio is presently 43.72%.

Wall Street Analyst Weigh In

Several research analysts have commented on IRMD shares. Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Lake Street Capital reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Weiss Ratings raised shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $120.00.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC raised its holdings in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after acquiring an additional 33,072 shares in the last quarter. Principal Financial Group Inc. bought a new stake in shares of iRadimed in the third quarter valued at about $422,000. Tudor Investment Corp ET AL bought a new stake in shares of iRadimed in the third quarter valued at about $666,000. RFG Advisory LLC bought a new stake in shares of iRadimed in the fourth quarter valued at about $1,594,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of iRadimed in the fourth quarter valued at about $595,000. 92.34% of the stock is currently owned by institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.